Somatic cells for use in cell therapy
First Claim
1. A preserved cell preparation, comprising:
- lyophilized cells; and
at least one polyphenol selected from the group consisting of epigallocatechin gallate (EGCG), epicatechin gallate (ECG), epigallocatechin (EGC), epicatechin (EC), DL-Catechin (DL-C) and gallocatechin gallate (GCG), or mixtures thereof, the polyphenol being present in a concentration of from about 50 μ
M to about 4 mM,the preserved cell preparation being essentially free of one or more cryoprotecting agents selected from the group consisting of polyalcohols, DMSO and cryoprotecting proteins, andupon reconstitution of the preserved cell preparation, at least 60% of the lyophilized cells in the preserved cell preparation are viable and sufficient for use in cell therapy.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention generally concerns cell therapy and products for use in such therapy. Particularly, the invention provides a preserved cell preparation essentially free of one or more members of a group of cryoprotecting agents consisting of polyalcohols, DMSO and cryoprotecting proteins, the preserved cell preparation comprising somatic cells and at least one polyphenol, wherein upon reconstitution of cells in the cell preparation, at least a portion of said stem cells are viable, said portion being sufficient for use of the cell preparation in stem cell therapy. The invention also provides cells reconstituted from preserved somatic cells, and the use of the reconstituted cells in cell therapy. A preferred cell preparation in accordance with the invention comprises stem cells, preferably human stem cells.
-
Citations
7 Claims
-
1. A preserved cell preparation, comprising:
-
lyophilized cells; and at least one polyphenol selected from the group consisting of epigallocatechin gallate (EGCG), epicatechin gallate (ECG), epigallocatechin (EGC), epicatechin (EC), DL-Catechin (DL-C) and gallocatechin gallate (GCG), or mixtures thereof, the polyphenol being present in a concentration of from about 50 μ
M to about 4 mM,the preserved cell preparation being essentially free of one or more cryoprotecting agents selected from the group consisting of polyalcohols, DMSO and cryoprotecting proteins, and upon reconstitution of the preserved cell preparation, at least 60% of the lyophilized cells in the preserved cell preparation are viable and sufficient for use in cell therapy. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
Specification